Monday, August 27, 2012

ImmunoGen Gapped Up 8% - IMGN, OESX, MTB, VRNG

ImmunoGen, Inc. (NASDAQ:IMGN) shares gained 8% to $14.92 after partner Roche Holding AG said its experimental breast cancer drug significantly extended the lives of patients when compared with standard therapy. The treatment, dubbed T-DM1, for people with HER2-positive metastatic breast cancer, combines Basel, Switzerland-based Roche’s Herceptin with ImmunoGen’s technology that helps the treatment carry chemotherapy directly into malignant cells while bypassing healthy ones.

Can IMGN Continue To Move Higher? Find Out Here

Orion Energy Systems, Inc. (NYSEAMEX:OESX), in August 2012, received a subpoena issued by the staff of the Securities and Exchange Commission requesting certain documents and information generally related to the Company’s financial reporting of its sales of solar photovoltaic systems, among other matters.

M&T Bank Corporation (NYSE:MTB) stock increased 1.32% to $87 in the pre-market hour after Hudson City Bancorp and M&T Bank Corporation announced they have entered into a definitive agreement under which Hudson City will merge into a subsidiary of M&T. Each Hudson City share will receive consideration valued at 0.08403 of an M&T share in the form of either M&T stock or cash, based upon the election of each Hudson City shareholder.

Additionally, the company announced that it has declared a quarterly cash dividend of $.70 per share on its common stock. The dividend will be payable September 28, 2012 to shareholders of record at the close of business on September 4, 2012.

Vringo, Inc. (NYSEAMEX:VRNG) stock declined 6% to $3.34 in the opening session. There are less than two months left until Vringo and Google go head-to-head in court. Vringo has emerged as a $200 million company largely due to its lawsuit threats against Google and other search engines like AOL.

Can VRNG Bounce Back Now? Find Out Here

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer